Valuation: 3SBio Inc.

Capitalization 67.66B 73.96B 9.42B 8.09B 7.53B 7.01B 12.93B 812B 14.44B 91.02B 34.36B 381B 35.35B 34.62B 1,399B P/E ratio 2025 *
12.2x
P/E ratio 2026 * 23.9x
Enterprise value 66.01B 72.15B 9.19B 7.89B 7.35B 6.84B 12.62B 792B 14.09B 88.8B 33.52B 371B 34.49B 33.77B 1,365B EV / Sales 2025 *
4.39x
EV / Sales 2026 * 5.53x
Free-Float
72.15%
Yield 2025 *
0.82%
Yield 2026 * 1.36%
More valuation ratios * Estimated data
Dynamic Chart
1 day+2.45%
1 week+24.65%
Current month+32.56%
1 month+46.15%
3 months+162.12%
6 months+405.65%
Current year+415.62%
More quotes
1 week 24.7
Extreme 24.7
31.7
1 month 20.2
Extreme 20.2
31.7
Current year 5.6
Extreme 5.6
31.7
1 year 5.47
Extreme 5.47
31.7
3 years 4.86
Extreme 4.86
31.7
5 years 4.72
Extreme 4.72
31.7
10 years 4.72
Extreme 4.72
31.7
More quotes
Manager TitleAgeSince
Chief Executive Officer 62 31/12/2005
Director of Finance/CFO - 02/07/2023
Corporate Officer/Principal 55 26/11/2014
Director TitleAgeSince
Chairman 62 02/04/2012
Director/Board Member 55 10/06/2012
Director/Board Member 56 31/05/2015
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+2.45%+24.65%+375.72%+449.04% 9.42B
+3.62%+6.83%-17.27%-13.24% 81.33B
-1.36%-4.44%-49.17%-7.53% 57.33B
-1.78%+5.10%+23.65%+29.75% 53.86B
+0.49%+2.28%+27.49%+106.34% 38.73B
-0.06%+10.55%+118.53%+146.33% 19.4B
+0.31%+11.62%+86.31%+820.19% 18.86B
-2.88%-6.87%-44.51%-41.69% 18.31B
-0.04%-.--%+75.97%+143.35% 14.02B
-1.57%-1.06%+3.81%-13.95% 13.14B
Average +0.42%+4.39%+60.05%+161.86% 32.44B
Weighted average by Cap. +0.71%+2.92%+18.13%+85.73%
See all sector performances

Financials

2025 *2026 *
Net sales 15.04B 16.44B 2.09B 1.8B 1.67B 1.56B 2.87B 180B 3.21B 20.23B 7.64B 84.58B 7.86B 7.69B 311B 11.65B 12.73B 1.62B 1.39B 1.3B 1.21B 2.23B 140B 2.49B 15.67B 5.92B 65.51B 6.09B 5.96B 241B
Net income 5.68B 6.21B 792M 679M 633M 589M 1.09B 68.17B 1.21B 7.64B 2.89B 31.96B 2.97B 2.91B 117B 2.94B 3.21B 409M 351M 327M 304M 562M 35.25B 627M 3.95B 1.49B 16.53B 1.54B 1.5B 60.75B
Net Debt -1.65B -1.81B -230M -198M -184M -171M -316M -19.85B -353M -2.23B -840M -9.31B -865M -847M -34.21B -3.22B -3.52B -448M -384M -358M -333M -615M -38.59B -687M -4.33B -1.63B -18.09B -1.68B -1.65B -66.5B
More financial data * Estimated data
Logo 3SBio Inc.
3SBio Inc is an investment holding company mainly engaged in the development, production, marketing and sale of pharmaceutical products. The Company’s core products include several biopharmaceutical drugs, TPIAO, recombinant human erythropoietin(rhEPO) products, with brand of EPIAO and SEPO, Yisaipu, Cipterbin and a small molecule drug, Mandi and tumor necrosis factor (TNF). Through its subsidiaries, the Company is engaged in project management and consultation. The Company still engages in developing innovative biological products, including mAbs, bi-specific antibodies and fusion proteins, and a number of small molecule drugs, both innovative and generic, in the areas of nephrology, oncology, auto-immune and inflammatory diseases, ophthalmology and dermatological diseases. The Company distributes its products within the domestic market and to overseas markets.
Employees
5,577
More about the company
Date Price Change Volume
18/07/25 31.35 $ +2.45% 31,479,470
17/07/25 30.60 $ +9.48% 61,168,310
16/07/25 27.95 $ -2.27% 30,047,700
15/07/25 28.60 $ +1.42% 39,234,220
14/07/25 28.20 $ +12.13% 67,645,990

Delayed Quote Hong Kong S.E., July 18, 2025 at 09:08 am

More quotes
Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
28.68CNY
Average target price
20.00CNY
Spread / Average Target
-30.26%
Consensus

Quarterly revenue - Rate of surprise